Clinical, economic, and quality of life impact of atrial fibrillation.

@article{Sanoski2009ClinicalEA,
  title={Clinical, economic, and quality of life impact of atrial fibrillation.},
  author={Cynthia A. Sanoski},
  journal={Journal of managed care pharmacy : JMCP},
  year={2009},
  volume={15 6 Suppl B},
  pages={
          S4-9
        }
}
  • C. Sanoski
  • Published 1 August 2009
  • Medicine
  • Journal of managed care pharmacy : JMCP
BACKGROUND Atrial fibrillation (AF) is a common, age-related arrhythmia that disproportionately affects men, adversely affects quality of life, and causes considerable morbidity and mortality. OBJECTIVES To describe trends in the prevalence and incidence of AF in the United States; discuss the etiologies and complications of AF; characterize the economic burden of AF; and predict an individual's risk for developing AF and AF-related stroke. SUMMARY The prevalence and incidence of AF in the… 
View on PubMed
jmcp.org
49 Citations
Highly Influential Citations
3
Background Citations
18
Methods Citations
1
Results Citations
2

49 Citations

Citation Type

Citation Type

Representing the patient perspective in the treatment of atrial fibrillation.
  • S. Pedersen, N. Kupper
  • Medicine
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2010
TLDR
Atrial fibrillation is the most common heart rhythm disorder associated with increased risk of morbidity, mortality, hospitalization, poor quality of life (QoL), and increased health care utilization, with the rise in the prevalence primarily attributed to the aging population and improved treatment options for coronary artery disease, heart failure, and hypertension.
[Atrial fibrillation--epidemiologic, economic and individual burden of disease].
TLDR
With an increasing ageing of the society it is suggested to ensure that care management for patients with AF will be optimized, particularly the symptomatic form.
Update on anti-coagulation in atrial fibrillation
  • J. Kreuzer
  • Medicine, Biology
    QJM : monthly journal of the Association of Physicians
  • 2011
TLDR
The novel, oral, direct thrombin inhibitor, dabigatran etexilate, recently licensed by the US Food and Drug Administration and Health Canada has shown improved efficacy and safety compared with warfarin for stroke prevention in AF, and has the potential to replacewarfarin in this indication.
The costs of atrial fibrillation in patients with cardiovascular comorbidities--a longitudinal analysis of German health insurance data.
  • T. Reinhold, C. Lindig, S. Willich, B. Brüggenjürgen
  • Medicine, Political Science
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2011
TLDR
Atrial fibrillation is associated with significant economic costs from the perspective of statutory health insurance, and an efficient management of inpatient treatment structures as well as a cost-outcome-oriented drug regime seems to be outstandingly important.
Inflammatory responses in the atria: should they stay or should they go?
  • H. Duffy
  • Biology, Medicine
    Heart rhythm
  • 2011
Overview of pathophysiology and management of AF
TLDR
The important contributions of nurses in optimising the care of patients who have AF are discussed and key topics for patient education and support are identified.
RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers
TLDR
The RHYTHM-AF registry will provide insight into regional variability of antiarrhythmic and antithrombotic treatment of atrial fibrillation, the appropriateness of such treatments with respect to outcomes, and their cost-efficacy.
An Observational, Prospective Survey Assessing the Control of Atrial Fibrillation in Asia Pacific: Rationale and Design of the RecordAF-AP Registry
TLDR
RecordAF-AP will assess the real-life management of atrial fibrillation patients in Asia Pacific, including a comparison of clinical outcomes in rhythm versus rate control strategies, providing much needed insight into the costs, treatment choices and clinical outcomes of AF patients in this region.
Rate vs rhythm control in patients with atrial fibrillation and heart failure: a systematic review and meta-analysis of randomised controlled trials.
Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US
TLDR
The generalizability of cost-effectiveness results of anticoagulant therapy in AF based on clinical trial data must be confirmed by comparative effectiveness research conducted in the real-world setting.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Quality of life in patients with silent atrial fibrillation
TLDR
Symptoms relevant for AF were selected from Bubien and Kay's symptom checklist, including palpitations, dyspnoea, dizziness, exercise intolerance, chest discomfort, and syncope, and its effect on quality of life (QoL) has not yet been established.
Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study
TLDR
Lifetime risks for development of AF are 1 in 4 for men and women 40 years of age and older, even in the absence of antecedent congestive heart failure or myocardial infarction, and substantial lifetime risks underscore the major public health burden posed by AF.
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
TLDR
The 2 existing classification schemes and especially a new stroke risk index, CHADS, can quantify risk of stroke for patients who have AF and may aid in selection of antithrombotic therapy.
Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999: Implications for Primary Prevention
TLDR
Hospitalizations for atrial fibrillation have increased dramatically (2- to 3-fold) in recent years, and the public health burden of atrialfibrillation is enormous and expected to continue to increase over the next decades.
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
TLDR
The data suggest that the elderly are particularly vulnerable to stroke when atrial fibrillation is present, and the effects of hypertension, coronary heart disease, and cardiac failure on the risk of stroke became progressively weaker with increasing age.
Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study
TLDR
Individuals with AF or CHF who subsequently develop the other condition have a poor prognosis, and additional studies addressing the pathogenesis, prevention, and optimal management of the joint occurrence of AF and CHF appear warranted.
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
TLDR
In addition to intrinsic cardiac causes such as valve disease and congestive heart failure, risk factors for cardiovascular disease also predispose to atrial fibrillation.
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.
TLDR
The risks and benefits of antithrombotic therapy in older individuals are important considerations in stroke prevention in atrial fibrillation patients.
Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
...
1
2
3
4
...